Publicaciones en las que colabora con José Ramón Blanco Ramos (6)

2021

  1. Maraviroc prevents hcc development by suppressing macrophages and the liver progenitor cell response in a murine chronic liver disease model

    Cancers, Vol. 13, Núm. 19

2018

  1. Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet

    Translational Research, Vol. 196, pp. 17-30

2016

  1. Off-label use of maraviroc in clinical practice

    Expert Review of Anti-Infective Therapy

2014

  1. Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 7, pp. 1903-1910

2013

  1. Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model

    PLoS ONE, Vol. 8, Núm. 1

2012

  1. Could CCR5 be a potential target against infections?

    Expert Review of Anti-Infective Therapy